Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease. Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids. Edema may occur occasionally with or without congestive heart failure. Concomitant administration of adrenal steroids or ACTH may add to the edema. In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months. This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.
Awareness and educational efforts are working to help prevent anabolic steroid abuse in schools and communities. The Adolescents Training and Learning to Avoid Steroids (ATLAS) and the Athletes Targeting Healthy Exercise and Nutrition Alternatives (ATHENA) programs, funded by the NIDA, and supported by the Oregon Health & Science University programs is teaching athletes that they do not need steroids to build powerful muscles and improve athletic performance. These programs provide weight-training and nutrition alternatives, increase healthy behaviors, less likelihood to try steroids, and less likelihood to engage in other dangerous behaviors such as drinking and driving, use of marijuana and alcohol , and and improved body image. Bother Congress and the Substance Abuse and Mental Health Services Administration endorsed these model prevention programs. 4
The ideal researcher is someone who has a couple cycles of anabolics under their belt. Ideally, the researcher is more experienced when it comes to SARMs.
They have already been lifting for a couple years and hit their genetic peak and want to pack on some more size in an 8-12 week time frame.
Researchers will not mind a little more natural testosterone suppression than what you get get with Ostarine or Andarine.
This is definitely not for first time anabolic or SARM users. LGD 4033 is too potent a mass builder for time users. You would honestly be better off and would see just as good of results with Ostarine.
Nonetheless, ligandrol is a very potent mass builder than ideal for researchers who want to add appreciable strength and size over a bulking cycle without having to worry about some of horrible side effects of AAS or designer steroids.